While first‐ and second‐generation (first‐ and second‐gen) EGFR tyrosine kinase inhibitors (TKIs) have been effective in treating NSCLC, their efficacy is hampered by the emergence of resistance mutations, particularly the EGFR T790M mutation, as well as suboptimal central nervous system (CNS) penetration [7, 8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.